| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 214.951 | 207.673 | 206.200 | 210.407 | 209.135 | 227.086 | 224.465 | 256.295 | 247.621 | 191.234 |
| Total Income - EUR | 214.952 | 225.568 | 224.399 | 229.999 | 228.768 | 227.833 | 224.732 | 264.276 | 260.358 | 226.763 |
| Total Expenses - EUR | 198.123 | 200.072 | 212.995 | 213.080 | 213.244 | 204.385 | 203.153 | 247.281 | 257.719 | 209.401 |
| Gross Profit/Loss - EUR | 16.829 | 25.497 | 11.404 | 16.919 | 15.524 | 23.448 | 21.578 | 16.995 | 2.638 | 17.362 |
| Net Profit/Loss - EUR | 14.136 | 21.417 | 9.409 | 14.619 | 13.236 | 21.401 | 20.438 | 15.245 | 752 | 14.917 |
| Employees | 8 | 8 | 9 | 7 | 7 | 5 | 4 | 8 | 9 | 6 |
Check the financial reports for the company - Balbiotil Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 42.883 | 33.733 | 23.705 | 9.954 | 960 |
| Current Assets | 38.196 | 37.739 | 34.908 | 29.643 | 29.972 | 43.632 | 107.924 | 134.256 | 135.115 | 119.214 |
| Inventories | 34.040 | 34.710 | 32.218 | 27.229 | 23.831 | 25.771 | 27.090 | 39.114 | 35.424 | 16.598 |
| Receivables | 1.800 | 794 | 846 | 104 | 830 | 16.260 | 78.080 | 81.670 | 96.325 | 96.239 |
| Cash | 2.356 | 2.235 | 1.844 | 2.310 | 5.311 | 1.602 | 2.753 | 13.472 | 3.365 | 6.376 |
| Shareholders Funds | 18.622 | 21.684 | 17.855 | 19.886 | 17.658 | 30.857 | 50.612 | 66.014 | 66.566 | 81.111 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 827 | 809 | 811 | 809 | 804 |
| Debts | 19.573 | 16.055 | 17.053 | 9.757 | 12.314 | 55.658 | 91.045 | 91.947 | 78.503 | 39.063 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4778 - 4778" | |||||||||
| CAEN Financial Year |
4778
|
|||||||||
Comments - Balbiotil Srl